Phase 3 N=157 The Study Of Fluconazole For Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Therapeutic Outcome: Response Rate — 33.7; 54.2; 74.7 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=215 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent Vulvovaginal Candidiasis
Primary: The Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes Through Week 48 of the Study in the Intent-to-treat Population. — 2; 3; 0; 2 Participants
Phase 2 N=137 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
Vulvovaginitis · Yeast Infection · Yeast Infection Vaginal
Primary: Clinical Outcome Assessed at Test of Cure Visit — 13; 12; 24; 12 Participants
Phase 4 N=115 An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis
Vulva; Candidiasis
Primary: Mean Time to Itch Relief — 13.36 minutes
Phase 3 N=330 A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population. — 3.9; 39.4…
Phase 4 N=240 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
Candidiasis, Vulvovaginal
Primary: Therapeutic Efficacy 1 — 102; 98 participants — p=0.925
Phase 3 N=150 Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure — 7; 10; 23 Participants
Phase 4 N=140 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Mycological Cure 1 — 46; 47 Participants
Phase 3 N=326 A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-Verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-Treat Population — 6.7; 42.8…
N/A N=144 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
Vulvovaginal Candidiasis
Primary: Candida Culture Free After Maintenance Therapy — 18; 19; 9 participants
Phase 2 N=55 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
Candidiasis, Vulvovaginal
Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants
Phase 3 N=455 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 119; 37; 69; 47 Participants
Phase 3 N=219 Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population — 5.1; 42.2…
Phase 2 N=186 Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 9; 14; 13; 14 Participants
Phase 2 N=188 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period — 72; 79; 10; 25 AEs
Phase 3 N=260 Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Recurrent Vulvovaginal Candidiasis
Primary: Clinical Success — 85; 69; 45; 61 Participants
N/A N=26 Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants
Phase 2 N=229 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Vulvovaginal Candidiasis
Primary: Dose-response of Clinical and Mycological (Global) Therapeutic Response — 31.7; 48.7; 47.6; 53.8 percentage of patients cured — p=0.0630
Phase 3 N=376 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 95; 28; 93; 70 Participants
N/A N=23 Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate — 9 Participants
Phase 2 N=234 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
Bacterial Vaginosis · Candidiasis · Trichomoniasis
Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…
Phase 3 N=160 A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis
Vaginitis · Infectious Vaginosis
Primary: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment — 67.1; 79.2; 32.9; 20.8 Percentage of Participants
N/A N=50 Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis
Vaginitis and Vulvovaginitis
Primary: Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit — 13 Participants
Phase 2 N=9 CC-10004 For The Treatment Of Vulvodynia
Vulvodynia
Primary: Global Response Assessment — 5 participants
Phase 3 N=578 Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
HIV Infections
Primary: Clinical Cure (Defined as a Complete Resolution of Signs and Symptoms) After 14 Days of Treatment at the Test of Cure Visit (Day 17-Day 22) Using Murray Scoring Scale…
Phase 3 N=221 Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis
HIV-1 Infection
Primary: Number of Participants With Clinical Efficacy — 76; 73 participants
Phase 2 N=228 LACTIN-V Study for Recurrent Bacterial Vaginosis
Bacterial Vaginosis
Primary: The Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) in Each Study Arm. — 0.11; 0.07 proportion of…
Phase 2 N=4 CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Candidiasis, Chronic Mucocutaneous
Primary: Clinical Response to Treatment of Mucocutaneous Candidiasis — 4 Participants
N/A N=611 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
Vulvovaginal Candidiasis
Primary: The Test of Equivalence Between the Test and Reference Products Was Based on the Therapeutic Cure Rates at Visit 3/Test-of-Cure. — 73; 73; 16 participants
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants